Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Poll Finds 65% Self-Inspection Rate for “Stable Supply Medicines”
March 28, 2022
- FPMAJ Hammers Out FY2022 Project Plans, Revs Up for Off-Year Revision Debate
March 28, 2022
- FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
March 28, 2022
- JGA to Employ 3rd Party Auditor on Trial Basis to Ensure Manufacturing Compliance
March 28, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- FPMAJ Launches Taskforce to Conduct Supply Surveys for 130 APIs
March 25, 2022
- Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
March 22, 2022
- FPMAJ Should Take Lead to Address Drug Supply Issues: JMA Chief
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Drug Makers Launch Digital Health Advocacy Group, Mitsubishi Tanabe Exec Serves as Head
March 15, 2022
- Switch to Original Drugs Up Nearly 5-Fold YOY in 6-Month Period from August 2021: NPhA Survey
March 15, 2022
- API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
- List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
- Therapeutic Value of Kampo Medicines for COVID-19 Being Examined
March 11, 2022
- Generic/Biosimilar Association Proposes Establishing Inspector Database to Stem GMP Violations
March 9, 2022
- Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
March 8, 2022
- Antimicrobial Use Fell 30-40% Between January 2019 and January 2021: JPA
March 7, 2022
- JMA Calls for Investigation into Increasing Cases of Off-Label Use of GLP-1 Agents
March 4, 2022
- FPMAJ Starts Survey on Industry’s Inspection Status for “Stable Supply Medicines”
March 3, 2022
- JPMA, Overseas Pharma Groups Call for Improvements in Access to COVID-19 Vaccines
March 1, 2022
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…